New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

August 31, 2012Jill SteinLenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patient
World medicine November 21,2023
Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

August 31, 2012Jill SteinLenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patient
World medicine November 21,2023
Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

May 22, 2017Angelica WelchDaniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.Daniel J. Landsburg, MDFor patients with double-hit lymphom
World medicine November 21,2023
Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

May 22, 2017Angelica WelchDaniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.Daniel J. Landsburg, MDFor patients with double-hit lymphom
World medicine November 21,2023
Stem Cell Research Aims to Further Personalize Lung Cancer Care

Stem Cell Research Aims to Further Personalize Lung Cancer Care

August 8, 2017Gina ColumbusTushar Desai, MD, discusses his research in stem cells and why discovering which cells have the potential to form lung cancer is significant to the treatment paradigm.Tushar
World medicine November 21,2023
Stem Cell Research Aims to Further Personalize Lung Cancer Care

Stem Cell Research Aims to Further Personalize Lung Cancer Care

August 8, 2017Gina ColumbusTushar Desai, MD, discusses his research in stem cells and why discovering which cells have the potential to form lung cancer is significant to the treatment paradigm.Tushar
World medicine November 21,2023
Stem Cells Create a Therapeutic Niche

Stem Cells Create a Therapeutic Niche

October 18, 2014Surabhi Dangi-Garimella, PhDStem cell therapy has gained increasing traction in various therapeutic areas, from cancer to diabetes to ocular regeneration.Stem cell therapy has gained i
World medicine November 21,2023
Stem Cells Create a Therapeutic Niche

Stem Cells Create a Therapeutic Niche

October 18, 2014Surabhi Dangi-Garimella, PhDStem cell therapy has gained increasing traction in various therapeutic areas, from cancer to diabetes to ocular regeneration.Stem cell therapy has gained i
World medicine November 21,2023
Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

April 8, 2014Prerna Mewawalla, MDTo address the challenge of the limited availability of stem cell donors in non-Caucasians, it is vital that we increase awareness through more campaigns that are targ
World medicine November 21,2023
Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

April 8, 2014Prerna Mewawalla, MDTo address the challenge of the limited availability of stem cell donors in non-Caucasians, it is vital that we increase awareness through more campaigns that are targ
World medicine November 21,2023
Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 24, 2019Onclive TeamTwo doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results
World medicine November 21,2023
Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 24, 2019Onclive TeamTwo doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results
World medicine November 21,2023
Eltrombopag Approved in Europe for Severe Aplastic Anemia

Eltrombopag Approved in Europe for Severe Aplastic Anemia

September 2, 2015Silas InmanThe European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavil
World medicine November 21,2023
Eltrombopag Approved in Europe for Severe Aplastic Anemia

Eltrombopag Approved in Europe for Severe Aplastic Anemia

September 2, 2015Silas InmanThe European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavil
World medicine November 21,2023
Cancer Stem Cells Coming Into Sharper Focus

Cancer Stem Cells Coming Into Sharper Focus

November 11, 2015Jane de Lartigue, PhDParticular progress has been made in the development of small-molecule inhibitors of key signaling pathways that are responsible for the unique characteristics of
World medicine November 21,2023
Cancer Stem Cells Coming Into Sharper Focus

Cancer Stem Cells Coming Into Sharper Focus

November 11, 2015Jane de Lartigue, PhDParticular progress has been made in the development of small-molecule inhibitors of key signaling pathways that are responsible for the unique characteristics of
World medicine November 21,2023
Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

August 14, 2020Jessica HergertKami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges th
World medicine November 21,2023
Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

August 14, 2020Jessica HergertKami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges th
World medicine November 21,2023
Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

February 23, 2019Danielle TernyilaChristopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with hi
World medicine November 21,2023
Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

February 23, 2019Danielle TernyilaChristopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with hi
World medicine November 21,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com